>
Switch to:

Horizon Therapeutics Owner Earnings per Share (TTM)

: 2.35 (As of Sep. 2021)
View and export this data going back to 2011. Start your Free Trial

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Horizon Therapeutics's Owner Earnings per Share (TTM) ended in Sep. 2021 was $2.35. It's Price-to-Owner-Earnings ratio for today is 42.46.


The historical rank and industry rank for Horizon Therapeutics's Owner Earnings per Share (TTM) or its related term are showing as below:

NAS:HZNP' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.02   Med: 44.16   Max: 555.18
Current: 42.53

15.02
555.18

During the past 13 years, the highest Price-to-Owner-Earnings ratio of Horizon Therapeutics was 555.18. The lowest was 15.02. And the median was 44.16.


NAS:HZNP's Price-to-Owner-Earnings is ranked lower than
67% of the 470 Companies
in the Drug Manufacturers industry.

( Industry Median: 26.13 vs. NAS:HZNP: 42.53 )

Horizon Therapeutics's Earnings per Share (Diluted) for the three months ended in Sep. 2021 was $1.38. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 was $2.32. It's PE Ratio ratio for today is 43.01.

Horizon Therapeutics's EPS without NRI for the three months ended in Sep. 2021 was $1.38. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2021 was $2.32. It's PE Ratio without NRI ratio for today is 43.01.


Horizon Therapeutics Owner Earnings per Share (TTM) Historical Data

The historical data trend for Horizon Therapeutics's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Horizon Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Owner Earnings per Share (TTM)
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 -0.29 0.27 0.84 1.03

Horizon Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Owner Earnings per Share (TTM) Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 1.03 1.30 1.17 2.35

Competitive Comparison

For the Drug Manufacturers - General subindustry, Horizon Therapeutics's Owner Earnings per Share (TTM), along with its competitors' market caps and Owner Earnings per Share (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Horizon Therapeutics Owner Earnings per Share (TTM) Distribution

For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's Owner Earnings per Share (TTM) distribution charts can be found below:

* The bar in red indicates where Horizon Therapeutics's Owner Earnings per Share (TTM) falls into.



Horizon Therapeutics Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Horizon Therapeutics's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 552
Depreciation, Depletion and Amortization 327
Change In Deferred Tax -173
5Y Average of Maintenance Capital Expenditure 63
Change In Working Capital -88
Shares Outstanding (Diluted Average) 236

1. Start with "Net Income" from income statement. Horizon Therapeutics's Net Income for the trailing twelve months (TTM) ended in Sep. 2021 was $552 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Horizon Therapeutics's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Sep. 2021 was $327 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Horizon Therapeutics's Change In Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2021 was $-173 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $63 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Horizon Therapeutics's 5-Year Average Maintenance Capital Expenditure = $63 Mil

5. "Change In Working Capital" is from cashflow statement. Horizon Therapeutics's Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2021 was $-88 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Horizon Therapeutics's Shares Outstanding (Diluted Average) for the months ended in Sep. 2021 was 236.199 Mil.

Horizon Therapeutics's Onwer Earnings Per Share for Sep. 2021 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 551.866 +326.761+-173.346
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-62.944107939439+-87.514)/236.199
=2.35

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=99.785/2.35
=42.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Horizon Therapeutics Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Horizon Therapeutics Business Description

Horizon Therapeutics logo
Industry
Healthcare » Drug Manufacturers NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, 1st Floor, Dublin, IRL, D04 C5Y6
Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company has two reportable segments: orphan and rheumatology segment and the inflammation segment. It markets medicines in the areas of orphan diseases, rheumatology and inflammation division. The majority of revenue is generated in the United States.
Executives
Sherman Jeffrey W officer: EVP and Chief Medical Officer C/O IDM PHARMA, INC. 9 PARKER, SUITE 100 IRVINE CA 92618
Camardo Daniel A. officer: EVP and President, U.S. C/O HORIZON THERAPEUTICS, PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 D04 C5Y6
Konstantinovsky Irina officer: EVP, Chief Human Resources Off C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 4
Beeler Brian K officer: EVP, General Counsel C/O HORIZON PHARMA PLC 520 LAKE COOK ROAD, SUITE 520 DEERFIELD IL 60015
Hoelscher Paul W. officer: EVP, CFO 520 LAKE COOK ROAD, SUITE 520 C/O HORIZON PHARMA, INC. DEERFIELD IL 60062
Walbert Timothy P director, officer: Chairman, President and CEO 1033 SKOKIE BOULEVARD SUITE 355 NORTHBROOK IL 60062
Grey Michael G director C/O SGX PHARMACEUTICALS, INC. 10505 ROSELLE STREET SAN DIEGO CA 92121
Santini Gino director C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Karnani Vikram officer: EVP & President, International C/O HORIZON PHARMA PLC, CONNAUGHT HOUSE 1ST FLOOR, 1 BURLINGTON RD DUBLIN L2 4
Witz Pascale director C/O REGULUS THERAPEUTICS INC. 10614 SCIENCE CENTER DRIVE SAN DIEGO CA 92121
Shannon James Samuel director 28903 NORTH AVENUE PAINE VALENCIA CA 91355
Kent Jeff officer: See remarks C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 4
Moze Barry officer: EVP, Chief Admin. Officer C/O HORIZON PHARMA, INC. 520 EAST COOK ROAD, SUITE 520 DEERFIELD IL 60015
Mchugh Miles W officer: Sr VP & Princ. Acctg Officer C/O ACCRETIVE HEALTH, INC. 401 N. MICHIGAN AVE, SUITE 2700 CHICAGO IL 60611
Curtis Geoffrey M. officer: EVP, Corporate Affairs, CCO C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 L2 4

Horizon Therapeutics Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)